The latest price target for Tyra Biosciences (NASDAQ:TYRA) was reported by Piper Sandler on March 20, 2026. The analyst firm set a price target for $56.00 expecting TYRA to rise to within 12 months (a possible 49.25% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Tyra Biosciences (NASDAQ:TYRA) was provided by Piper Sandler, and Tyra Biosciences maintained their overweight rating.

The last upgrade for Tyra Biosciences Inc happened on October 18, 2024 when B of A Securities raised their price target to $31. B of A Securities previously had a neutral for Tyra Biosciences Inc.

There is no last downgrade for Tyra Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tyra Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tyra Biosciences was filed on March 20, 2026 so you should expect the next rating to be made available sometime around March 20, 2027.

While ratings are subjective and will change, the latest Tyra Biosciences (TYRA) rating was a maintained with a price target of $42.00 to $56.00. The current price Tyra Biosciences (TYRA) is trading at is $37.52, which is out of the analyst’s predicted range.